ECSP21023398A - Dosis unitaria de vacuna contra el dengue y administración de esta - Google Patents
Dosis unitaria de vacuna contra el dengue y administración de estaInfo
- Publication number
- ECSP21023398A ECSP21023398A ECSENADI202123398A ECDI202123398A ECSP21023398A EC SP21023398 A ECSP21023398 A EC SP21023398A EC SENADI202123398 A ECSENADI202123398 A EC SENADI202123398A EC DI202123398 A ECDI202123398 A EC DI202123398A EC SP21023398 A ECSP21023398 A EC SP21023398A
- Authority
- EC
- Ecuador
- Prior art keywords
- dengue
- unit dose
- tdv
- administration
- vaccine against
- Prior art date
Links
- 208000025729 dengue disease Diseases 0.000 title abstract 6
- 208000001490 Dengue Diseases 0.000 title abstract 5
- 206010012310 Dengue fever Diseases 0.000 title abstract 5
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000725619 Dengue virus Species 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención hace referencia a una dosis unitaria de una composición de vacuna contra el dengue y métodos y usos para prevenir la enfermedad del dengue, así como métodos para estimular una respuesta inmunitaria contra los cuatro serotipos del virus del dengue en un sujeto o población de sujetos. La dosis unitaria de una composición de vacuna contra el dengue incluye construcciones de cada serotipo del dengue, tal como TDV-1, TDV-2, TDV-3 y TDV-4, en diversas concentraciones, para mejorar la protección contra la infección por dengue.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18192787 | 2018-09-05 | ||
EP18192701 | 2018-09-05 | ||
EP18192800 | 2018-09-05 | ||
EP18192776 | 2018-09-05 | ||
EP18192717 | 2018-09-05 | ||
EP18192814 | 2018-09-05 | ||
EP18192711 | 2018-09-05 | ||
EP18192793 | 2018-09-05 | ||
EP19154334 | 2019-01-29 | ||
US16/295,611 US11464815B2 (en) | 2018-09-05 | 2019-03-07 | Dengue vaccine unit dose and administration thereof |
EP19161184 | 2019-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP21023398A true ECSP21023398A (es) | 2021-06-30 |
Family
ID=69722836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202123398A ECSP21023398A (es) | 2018-09-05 | 2021-04-05 | Dosis unitaria de vacuna contra el dengue y administración de esta |
Country Status (18)
Country | Link |
---|---|
US (3) | US11590221B2 (es) |
EP (3) | EP3620174B1 (es) |
JP (1) | JP2021536463A (es) |
KR (1) | KR20210071979A (es) |
CN (1) | CN112912106A (es) |
AU (1) | AU2019335006A1 (es) |
BR (1) | BR112021003962A2 (es) |
CA (1) | CA3111332A1 (es) |
CO (1) | CO2021003931A2 (es) |
DK (1) | DK3620174T3 (es) |
EC (1) | ECSP21023398A (es) |
ES (1) | ES2908304T3 (es) |
IL (2) | IL298307A (es) |
MX (1) | MX2021002586A (es) |
PE (1) | PE20211545A1 (es) |
PH (1) | PH12021550479A1 (es) |
SG (1) | SG11202102104SA (es) |
WO (1) | WO2020051334A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018012459A (es) * | 2016-04-13 | 2019-06-06 | Takeda Vaccines Inc | Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes. |
CA3111332A1 (en) * | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
WO2021174059A1 (en) * | 2020-02-27 | 2021-09-02 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
CN112813089A (zh) * | 2021-03-22 | 2021-05-18 | 苏州诺威百奥生物科技有限公司 | 黄病毒科检测用多位点重组抗原的制备方法 |
CN113913551B (zh) * | 2021-06-22 | 2022-05-13 | 中国检验检疫科学研究院 | 一种登革病毒分型的测序引物、检测方法及试剂盒 |
WO2024086605A1 (en) | 2022-10-18 | 2024-04-25 | Takeda Vaccines, Inc. | Dengue vaccine formulation |
EP4357464A1 (en) * | 2022-10-20 | 2024-04-24 | Takeda Vaccines, Inc. | A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4810092A (en) | 1986-02-21 | 1989-03-07 | Midac Corporation | Economical spectrometer unit having simplified structure |
JPH084508B2 (ja) | 1987-09-16 | 1996-01-24 | 国立予防衛生研究所長 | 組み換えワクチニアウイルス |
JP2511494B2 (ja) | 1988-05-12 | 1996-06-26 | 善治 松浦 | 日本脳炎ウイルス表面抗原蛋白質の製造法 |
US6184024B1 (en) | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
IL91304A0 (en) | 1988-08-20 | 1990-03-19 | Us Health | Recombinant vaccinia virus for prevention of disease caused by flavivirus |
US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
US5494671A (en) | 1990-08-27 | 1996-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | C-terminally truncated dengue and Japanese encephalitis virus envelope proteins |
DE69231570T2 (de) | 1991-09-19 | 2001-06-21 | Us Health | Chimäre und/oder wachstumgehemmte Flaviviren |
JPH05276941A (ja) | 1992-02-28 | 1993-10-26 | Nippon Zeon Co Ltd | フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法 |
CA2224724C (en) | 1995-05-24 | 2007-12-04 | Hawaii Biotechnology Group, Inc. | Subunit vaccine against flavivirus infection |
WO1996040933A1 (en) | 1995-06-07 | 1996-12-19 | The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
IL131600A0 (en) | 1997-02-28 | 2001-01-28 | Ora Vax Inc | Chimeric flavivirus vaccines |
AU9794198A (en) | 1997-10-08 | 1999-04-27 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Chimeric vaccine against tick-borne encephalitis virus |
CA2331368C (en) | 1998-06-04 | 2009-02-10 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nucleic acid vaccines for prevention of flavivirus infection |
PT2278012E (pt) | 2000-02-16 | 2015-11-30 | Univ Mahidol | Quimeras imunogénicas do vírus do dengue 2 |
CA2440593A1 (en) | 2001-03-12 | 2002-09-19 | Yale University | Compositions and methods comprising west nile virus polypeptides |
US20040259224A1 (en) | 2002-05-31 | 2004-12-23 | Farshad Guirakhoo | Tetravalent Dengue vaccines |
WO2006134443A1 (en) | 2005-06-17 | 2006-12-21 | Sanofi Pasteur | Dengue serotype 2 attenuated strain |
WO2007021672A2 (en) | 2005-08-10 | 2007-02-22 | Acambis Inc. | Vaccination against dengue virus infection |
FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
AP3172A (en) | 2007-07-13 | 2015-03-31 | Florida Gulf Coast University | Optimized dengue virus entry inhibitory peptide (DN81) |
SG157244A1 (en) | 2008-05-15 | 2009-12-29 | Mp Biomedicals Asia Pacific Pte Ltd | Point of care test for the detection of exposure or immunity to dengue virus |
WO2010085358A2 (en) | 2009-01-23 | 2010-07-29 | The Board Of Regents Of The University Of Texas System | Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof |
EP2438198A4 (en) | 2009-06-01 | 2014-05-14 | Inviragen Inc | COMPOSITIONS AND METHODS FOR THE DELIVERY OF VACCINES AGAINST DENGUE VIRUS |
US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
BRPI0904020B8 (pt) | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | composição vacinal contra o vírus da dengue, e, kit |
EP2353609A1 (en) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
TW201402143A (zh) | 2012-06-10 | 2014-01-16 | Inviragen Inc | 抗登革熱病毒疫苗之組成物及投藥方法 |
MY168959A (en) | 2012-07-24 | 2019-01-28 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
CN104812408A (zh) | 2012-07-24 | 2015-07-29 | 赛诺菲巴斯德有限公司 | 用于防止登革热病毒感染的疫苗组合物 |
TW201428101A (zh) | 2012-11-08 | 2014-07-16 | Inviragen Inc | 登革熱病毒血清型4型之建構物的組成物、方法及用途 |
CA2933472A1 (en) | 2012-12-14 | 2014-06-19 | Takeda Vaccines, Inc. | Compositions, methods of administration and uses for trivalent dengue virus formulations |
ES2933970T3 (es) | 2013-03-15 | 2023-02-15 | Takeda Vaccines Inc | Composiciones y métodos para construcciones quiméricas de virus del dengue en vacunas |
TW201620546A (zh) | 2014-09-02 | 2016-06-16 | 賽諾菲巴斯德公司 | 疫苗組合物 |
WO2017005654A1 (en) | 2015-07-03 | 2017-01-12 | Sanofi Pasteur | Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination. |
BR112017028212A2 (pt) | 2015-07-03 | 2018-09-11 | Sanofi Pasteur | vacinação concomitante contra dengue e febre amarela |
US10004795B2 (en) | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
MX2018012459A (es) * | 2016-04-13 | 2019-06-06 | Takeda Vaccines Inc | Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes. |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
CA3111332A1 (en) * | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
US11464815B2 (en) * | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
-
2019
- 2019-09-05 CA CA3111332A patent/CA3111332A1/en active Pending
- 2019-09-05 AU AU2019335006A patent/AU2019335006A1/en active Pending
- 2019-09-05 EP EP19195692.9A patent/EP3620174B1/en active Active
- 2019-09-05 JP JP2021512482A patent/JP2021536463A/ja active Pending
- 2019-09-05 WO PCT/US2019/049749 patent/WO2020051334A1/en active Application Filing
- 2019-09-05 BR BR112021003962-7A patent/BR112021003962A2/pt unknown
- 2019-09-05 PE PE2021000288A patent/PE20211545A1/es unknown
- 2019-09-05 US US16/561,953 patent/US11590221B2/en active Active
- 2019-09-05 MX MX2021002586A patent/MX2021002586A/es unknown
- 2019-09-05 ES ES19195692T patent/ES2908304T3/es active Active
- 2019-09-05 EP EP22151940.8A patent/EP4082568A1/en active Pending
- 2019-09-05 IL IL298307A patent/IL298307A/en unknown
- 2019-09-05 CN CN201980070866.0A patent/CN112912106A/zh active Pending
- 2019-09-05 KR KR1020217009759A patent/KR20210071979A/ko unknown
- 2019-09-05 DK DK19195692.9T patent/DK3620174T3/da active
- 2019-09-05 US US17/274,016 patent/US20220226401A1/en active Pending
- 2019-09-05 EP EP19769699.0A patent/EP3846849A1/en active Pending
- 2019-09-05 IL IL281177A patent/IL281177B2/en unknown
- 2019-09-05 SG SG11202102104SA patent/SG11202102104SA/en unknown
-
2021
- 2021-03-05 PH PH12021550479A patent/PH12021550479A1/en unknown
- 2021-03-29 CO CONC2021/0003931A patent/CO2021003931A2/es unknown
- 2021-04-05 EC ECSENADI202123398A patent/ECSP21023398A/es unknown
-
2023
- 2023-01-04 US US18/149,742 patent/US20230355748A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202102104SA (en) | 2021-04-29 |
US20230355748A1 (en) | 2023-11-09 |
EP3620174B1 (en) | 2022-01-19 |
PH12021550479A1 (en) | 2021-10-25 |
EP3620174A1 (en) | 2020-03-11 |
CO2021003931A2 (es) | 2021-04-19 |
IL281177B2 (en) | 2024-03-01 |
EP4082568A1 (en) | 2022-11-02 |
IL298307A (en) | 2023-01-01 |
AU2019335006A1 (en) | 2021-05-06 |
ES2908304T3 (es) | 2022-04-28 |
JP2021536463A (ja) | 2021-12-27 |
DK3620174T3 (da) | 2022-03-14 |
US11590221B2 (en) | 2023-02-28 |
CA3111332A1 (en) | 2020-03-12 |
WO2020051334A1 (en) | 2020-03-12 |
KR20210071979A (ko) | 2021-06-16 |
MX2021002586A (es) | 2021-06-08 |
EP3846849A1 (en) | 2021-07-14 |
CN112912106A (zh) | 2021-06-04 |
IL281177B1 (en) | 2023-11-01 |
US20200230230A1 (en) | 2020-07-23 |
BR112021003962A2 (pt) | 2021-05-25 |
PE20211545A1 (es) | 2021-08-16 |
IL281177A (en) | 2021-04-29 |
US20220226401A1 (en) | 2022-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP21023398A (es) | Dosis unitaria de vacuna contra el dengue y administración de esta | |
NI202000040A (es) | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos | |
BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
CL2018002549A1 (es) | Eliminación del virus de la hepatitis b con agentes antivirales | |
AR055603A1 (es) | Vacuna contra la infeccion por virus del dengue | |
UY37997A (es) | Agentes antivirales contra la hepatitis b | |
MX2017009308A (es) | Composiciones inmunogenicas para usar en vacunas neumococicas. | |
PE20151588A1 (es) | Vacuna contra el virus del dengue | |
CL2017001961A1 (es) | Vacuna bivalente contra el virus de gripe porcina | |
CO2020001960A2 (es) | Formulaciones de anticuerpos anti-c5 de alta concentración | |
CL2019003091A1 (es) | Terapia de combinación. | |
AR064009A1 (es) | Metodo de inmunizacion contra los 4 serotipos del dengue | |
AR089797A1 (es) | Vacunas contra clostridum difficile que comprenden toxinas recombinantes | |
ECSP18020055A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
AR061887A1 (es) | Una composicion de vacuna contra el dengue | |
UY36518A (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
CO6460752A2 (es) | Respuesta inmunitaria reforzada en especies aviares | |
CO2020008231A2 (es) | Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto | |
AR108829A1 (es) | Vacuna contra virus de bronquitis infecciosa | |
CL2019003572A1 (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. | |
BR112017028212A2 (pt) | vacinação concomitante contra dengue e febre amarela | |
BR112015021523A2 (pt) | composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa | |
BR112019006802A2 (pt) | compostos e métodos para diagnóstico e tratamento de infecções virais | |
NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
CO2023003242A2 (es) | Vacuna contra el coronavirus y procedimiento para la preparación de la misma |